Inhibiting BTK has yielded remarkable gains for patients with B-cell malignancies, and the development of pirtobrutinib furthers these gains by introducing a new treatment option for patients with CLL/SLL, MCL, and other lymphomas. The gene discussed is BTK; the disease is lymphoma.